International Journal of Endocrinology / 2019 / Article / Tab 2

Research Article

Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism

Table 2

Sociodemographic and clinical features of patients and tumour characteristics according to WHO tumour classification (grading).
(a)

NET G1NET G2NEC

Total no. of patients ()158 (64.0)61 (24.7)28 (11.3)

(b)

NET G1NET G2NEC

Gender ()
 Male (), (%)65 (55.1)37 (31.4)16 (13.6)0.020
 Female (), (%)93 (72.1)24 (18.6)12 (9.3)

Age (), years (mean (SD))58.3 (12.8)59.8 (12.7)63.0 (12.9)0.176
Age at diagnosis (), years (median range)54.7 (15-85)56.5 (32-80)62.5 (39-84)0.017

Weight (), kg (mean (SD))71.8 (13.2)76.9 (17.5)68.7 (10.8)0.049
BMI (), kg·m-2 (mean (SD))27.0 (4.6)28.6 (5.7)24.6 (3.1)0.015

Comorbidities (), (%)105 out of 147 (71.4)44 out of 58 (75.8)15 out of 26 (57.6)0.233
Arterial hypertension (), (%)29 out of 150 (19.3)5 out of 58 (8.6)3 out of 27 (11.1)0.139
Diabetes mellitus (), (%)17 out of 149 (11.4)4 out of 58 (6.9)1 out of 27 (3.7)0.417
Dyslipidaemia (), (%)15 out of 154 (9.7)3 out of 58 (5.1)3 out of 27 (11.1)0.508
Cardiovascular disease (), (%)8 out of 150 (5.3)2 out of 58 (3.4)1 out of 27 (3.7)0.897
Family history of nonendocrine neoplasm (), (%)51 out of 105 (48.6)22 out of 42 (52.4)6 out of 20 (30.0)0.254

Smoking (), (%)3 out of 110 (2.7)4 out of 42 (9.5)3 out of 21 (14.3)0.007
Alcohol consumption (), (%)38 out of 106 (35.8)22 out of 37 (59.5)10 out of 20 (50.0)0.037

Tumour dimension (), mm (mean (SD))21.3 (19.9)32.7 (23.5)51.7 (34.9)<0.001
Vascular invasion (), (%)34 out of 106 (32.1)24 out of 41 (58.5)9 out of 15 (60.0)0.004
Lymphatic invasion (), (%)39 out of 103 (37.8)25 out of 36 (69.4)11 out of 16 (68.7)0.001
Perineural invasion (), (%)26 out of 84 (31.0)9 out of 25 (36.0)7 out of 10 (70.0)0.064

(c)

NET G1NET G2

Hormonal status
Functioning ()a17 out of 32 (53.1)6 out of 32 (18.6)
 Carcinoid ()b8 out of 17 (47.0)5 out of 17 (29.4)
 Gastrinoma ()c2 out of 4 (50.0)1 out of 4 (25.0)
 Insulinoma ()d7 out of 11 (63.6)0
Nonfunctioning, ()e12 out of 20 (60.0)5 out of 20 (25.0)

(d)

NET G1NET G2NEC

MEN-1 syndrome ()§2 out of 137 (1.5)2 out of 51 (3.9)0 out of 25 (0.0)0.575

Stage ()
 Localized, (%)51 out of 114 (44.7)11 out of 48 (22.9)4 out of 24 (16.7)0.001
 Locoregional, (%)26 out of 114 (22.8)10 out of 48 (20.8)2 out of 24 (8.3)
 Disseminated, (%)37 out of 114 (32.5)27 out of 48 (56.3)18 out of 24 (75.0)

Cases missing WHO tumour classification grading: a, b, c, d, and e. §Cases reported as not presenting MEN-1 syndrome clinical features (no genetic testing was performed for unsuspicious cases).

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.